Log in Free sign up

Clearside Biomedical (CLSD) News and press releases

News

From Benzinga Pro

Clearside Biomedical: Q1 Earnings Insights

Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Clearside Biomedical Q1 EPS $(0.13) Misses $(0.08) Estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.08) by 62.5 percent. This is unchanged from the same period last year.

Earnings Scheduled For May 11, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Clearside Biomedical Says Poster Presentation At ARVO 2022 Annual Meeting Demonstrates Versatility Of Suprachoroidal Delivery Technology

News, FDA, Events

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology - Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing

20 Stocks Moving in Wednesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) shares rose 100.9% to $2.13 in pre-market trading after jumping over 16% on Tuesday. Cosmos Holdings recently posted FY21 adjusted net income of $384K.

Bausch + Lomb And Clearside Biomedical Announce The U.S. Commercial Launch Of XIPERE For Suprachoroidal Use For The Treatment Of Macular Edema Associated With Uveitis

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside"), a biopharmaceutical company

30 Stocks Moving in Tuesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Smart for Life, Inc. (NASDAQ: SMFL) rose 75.3% to $1.63 in pre-market trading. Smart For Life recently said it is launching various products under the Doctors Scientific Organica brand on Amazon Singapore.

68 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.

38 Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Monday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

95 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.51.

Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Orphazyme Shares Plunge

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq dropping 150 points on Friday.

12 Health Care Stocks Moving In Friday's Intraday Session

Intraday Update, Markets, Movers

Mid-Day Market Update: Gold Down 1%; Clearside Biomedical Shares Jump

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded mixed midway through trading, with the Nasdaq dropping around 100 points on Friday.

50 Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Marygold Companies (NYSE: MGLD) jumped 189.4% to $6.28 after dropping 21% on Thursday.

Why Clearside Biomedical Shares Are Surging Today

Earnings, News, Penny Stocks, Movers, Trading Ideas

Clearside Biomedical Inc (NASDAQ: CLSD) shares are trading higher Friday after the company reported better-than-expected fourth-quarter financial results.

JMP Securities Maintains Market Outperform on Clearside Biomedical, Lowers Price Target to $10

News, Price Target, Analyst Ratings

JMP Securities analyst Jonathan Wolleben maintains Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and lowers the price target from $11 to $10.

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

30 Stocks Moving in Friday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Benzinga's After-Hours Movers & News: DocuSign, Clearside Biomedical And More

News, Penny Stocks, Small Cap, After-Hours Center, Trading Ideas

Benzinga's “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's Movers tool. Benzinga Pro users can cross-reference the Movers tool with the Benzinga Pro News tool to identify potential news catalysts moving stocks.

Press releases

From Benzinga Pro

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

- First Approved Suprachoroidal Product, XIPERE®, Now Commercially Available in U.S. - - Cohort 4 Enrolling at 1.0 mg Dose in CLS-AX OASIS Wet AMD Phase 1/2a Trial - - Management to Host Webcast and Conference

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology

Health Care, Press Releases

- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - - Dr. Thomas Ciulla to Participate in a Panel Discussion at Retina World Congress 2022 on May 12, 2022 -

Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022

News, Press Releases

ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners?

Opinion, Press Releases

NEW YORK, March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP.

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga., March 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of

Thinking about buying stock in Clearside Biomedical, Pearson, Paramount Gold Nevada, Hycroft Mining, or Alto Ingredients?

Opinion, Press Releases

NEW YORK, March 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, PSO, PZG, HYMC, and ALTO.

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors

News, Management, Press Releases

ALPHARETTA, Ga., March 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022

News, Press Releases

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal

Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022

News, Press Releases

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space